Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Ka Tat Siu, PhD, Janani Ramachandran, MA, Andrew J. Yee, MD, Homare Eda, MD PhD, Loredana Santo, MD, Elizabeth K. O'Donnell, MD, Cristina Panaroni, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur Raje, MD

Blood (2016) 128 (22): 3320.

https://doi.org/10.1182/blood.V128.22.3320.3320

Published: 2016

Journal Articles

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Ka Tat Siu, PhD, Homare Eda, MDPhD, Loredana Santo, MD, Janani Ramachandran, MA, Miroslav Koulnis, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4255.

https://doi.org/10.1182/blood.V126.23.4255.4255

Published: 2015

Journal Articles

Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts

Miroslav Koulnis, PhD, Homare Eda, MDPhD, Loredana Santo, MD, Ka Tat Siu, PhD, Janani Ramachandran, MA, Cristina Panaroni, PhD, Takaaki Tanaka, MD PhD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4200.

https://doi.org/10.1182/blood.V126.23.4200.4200

Published: 2015

Journal Articles

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Janani Ramachandran, MA, Loredana Santo, MD, Homare Eda, MDPhD, Dharminder Chauhan, PhD, Ka Tat Siu, PhD, Miroslav Koulnis, PhD, Dennis Huszar, PhD, Kenneth C Anderson, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 2992.

https://doi.org/10.1182/blood.V126.23.2992.2992

Published: 2015

Journal Articles

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, Janani Ramachandran, Diana D Cirstea, Homare Eda, Neeharika Nemani, Teru Hideshima, Chauhan Dharminder, Dennis Huszar, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2014) 124 (21): 5726.

https://doi.org/10.1182/blood.V124.21.5726.5726

Published: 2014

Journal Articles

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Yuko Mishima, Loredana Santo, Diana D. Cirstea, Homare Eda, Neeharika Nemani, Shirin Arastu-Kapur, Ph.D, Christopher J. Kirk, Ph.D, Simon S Jones, PhD, Raje Noopur, MD

Blood (2013) 122 (21): 4431.

https://doi.org/10.1182/blood.V122.21.4431.4431

Published: 2013

Journal Articles

Role Of Decorin In Multiple Myeloma (MM) Bone Marrow Microenvironment

Neeharika Nemani, Loredana Santo, Homare Eda, Diana Cirstea, Yuko Mishima, Chirayu Patel, Noopur Raje, MD

Blood (2013) 122 (21): 1851.

https://doi.org/10.1182/blood.V122.21.1851.1851

Published: 2013

Journal Articles

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Homare Eda, Loredana Santo, Diana D Cirstea, Andrew J Yee, Tyler A Scullen, Neeharika Nemani, Yuko Mishima, Shirin Arastu-Kapur, Erica Evans, Juswinder Singh, Christopher J Kirk, William F Westlin, Noopur S Raje

Blood (2013) 122 (21): 682.

https://doi.org/10.1182/blood.V122.21.682.682

Published: 2013

Journal Articles

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Erica Evans, Juswinder Singh, Wes Westlin, Noopur Raje

Blood (2012) 120 (21): 1822.

https://doi.org/10.1182/blood.V120.21.1822.1822

Published: 2012

Journal Articles

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Loredana Santo, Diana Cirstea, Bin Wang, Tso-Pang Yao, Joy Y. Wu, Peter Waterman, Derrick Jeon, Mary Bouxsein, Leeann Louis, Sutada Lotinun, Roland Baron, Homare Eda, Neeharika Nemani, Anuj Mahindra, Andrew J. Yee, Teru Hideshima, Kenneth C. Anderson, Simon S Jones, Noopur Raje, MD

Blood (2012) 120 (21): 328.

https://doi.org/10.1182/blood.V120.21.328.328

Published: 2012

Journal Articles

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Tyler Scullen, Sonia Vallet, Loredana Santo, Mariateresa Fulciniti, PhD, Homare Eda, Diana D. Cirstea, MD, Kishan Patel, Andrew Yee, Anuj Mahindra, MD, Noopur Raje, MD

Blood (2012) 120 (21): 1871.

https://doi.org/10.1182/blood.V120.21.1871.1871

Published: 2012

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Sonia Vallet, Noopur Raje

Blood (2012) 120 (21): 3989.

https://doi.org/10.1182/blood.V120.21.3989.3989

Published: 2012

Journal Articles

Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma

Anuj Mahindra, MD, Dora Dias-Santagata, Ph.D., Darrell Borger, Ph.D., Loredana Santo, Tyler A. Scullen, Andrew Yee, Homare Eda, Diana Cirstea, Anthony John Iafrate, M.D., Ph.D., Noopur Raje, MD

Blood (2012) 120 (21): 3990.

https://doi.org/10.1182/blood.V120.21.3990.3990

Published: 2012

Journal Articles

Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma

Diana Cirstea, Teru Hideshima, MD, PhD, Loredana Santo, Homare Eda, Tyler A. Scullen, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Yiguo Hu, Naoya Mimura, Jiro Minami, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M Guichard, Kenneth C. Anderson, Noopur Raje

Blood (2012) 120 (21): 4023.

https://doi.org/10.1182/blood.V120.21.4023.4023

Published: 2012

Journal Articles

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, John H. van Duzer, Ralph Mazitschek, Walter C. Ogier, Diana Cirstea, Scott Rodig, Homare Eda, Tyler Scullen, Miriam Canavese, James Bradner, Kenneth C. Anderson, Simon S. Jones, Noopur Raje

Blood (2012) 119 (11): 2579–2589.

https://doi.org/10.1182/blood-2011-10-387365

Published: 2012

Includes: Supplemental data

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Walter C Ogier, Diana D. Cirstea, MD, Scott Rodig, MD, PhD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Miriam Canavese, PhD, James E. Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2912.

https://doi.org/10.1182/blood.V118.21.2912.2912

Published: 2011

Journal Articles

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Homare Eda, MD, PhD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Anuj K. Mahindra, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Naoya Mimura, MD, PhD, Claire Fabre, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Kenneth C. Anderson, MD, Sylvie M Guichard, PharmD, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2916.

https://doi.org/10.1182/blood.V118.21.2916.2916

Published: 2011

Journal Articles

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Erica Evans, PhD, Juswinder Singh, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2882.

https://doi.org/10.1182/blood.V118.21.2882.2882

Published: 2011

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Noopur S. Raje, MD

Blood (2011) 118 (21): 1819.

https://doi.org/10.1182/blood.V118.21.1819.1819

Published: 2011

NARROW

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Role Of Decorin In Multiple Myeloma (MM) Bone Marrow Microenvironment

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma

Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only